FidoCure®
Data
11 posts with this tag
Safety and Toxicity of Small Molecule Inhibitors in Dogs with Spontaneously Occurring Malignancies — The Use of Real World Data
The VCS Virtual Conference was held from October 15 - 17, 2020. We had the honor of presenting our abstract during the event.
HSA Genomic Data: FidoCure® and Mason
On August 13, 2020, FidoCure® hosted a webinar with Dr. Nicola Mason, B.Vet.Med, PhD, DACVIM (Internal Medicine).
DataTargeted Therapy Efficacious Dose Finding: The Case for Agile Design
Why is the Palladia dose used at the clinic often different from the one on the FDA-approved label? Over 100 human targeted therapies have been approved, yet many doses were found to be incorrect in the post market stage. Why is that?
DataReal World Evidence: What is it? From Human Cancer Care to Veterinary Cancer Care
In human oncology, there has been a growing focus on analyzing data gathered from routine care, leading to a new field called real world evidence (RWE), which has taken off in recent years. The RWE approaches being used in human oncology can also be applied in the veterinary space.
Medical Brief: Exceptional Responders in Veterinary Cancer
One of the first pets to be enrolled in FidoCure®, Forrest, a 11 year-old Golden Retriever diagnosed with hemophagocytic histiocytic sarcoma, illustrates the value of evaluation of exceptional responders.
Data
